Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Twist Bioscience CFO Adam Laponis Sells $385K of Stock
Adam Laponis, CFO, sold 2,462 shares of Twist Bioscience Corp at $156.30 a share, worth $385K in total on Oct 9, 2026. Shares held after the trade: 98,114 (-2.4%).
Zeo ScientifiX, Inc. reported a working capital deficit of $1,915,000 as of October 31, 2025, which improved to a positive $65,000 by June 30, 2026. The company remains dependent on external investment capital to fund operations and faces significant risks regarding supply chain stability and its ability to continue as a going concern.
Grayscale Bittensor Trust (TAO) issued 253,100 shares to accredited investors in private placement transactions exempt from registration under Rule 506(c). The trust received an aggregate of 4,777.99171760 TAO tokens, valued at approximately $1.45 million, in exchange for the shares. As of October 13, 2026, the trust has 3,247,300 shares issued and outstanding.
Mika Nishimura, a Class II director and Chairperson of the Compensation Committee, has informed the Board of her intention not to stand for re-election at the upcoming 2026 annual meeting of stockholders. Her departure is not due to any disagreement with the company and she will continue to serve until the conclusion of the November 2026 meeting.
OKMIN RESOURCES, INC. is an early-stage exploration company with no proven oil and gas reserves and limited capital, necessitating future equity raises to fund operations. The company faces significant operational risks as a non-operator and is highly sensitive to volatile commodity prices, which recently spiked over $100 per barrel due to Middle East conflicts.
Senti Biosciences Holdings, Inc. convened its 2026 Annual Meeting of Stockholders on October 8, 2026, but adjourned the meeting without conducting any business. The adjournment was intended to provide additional time to solicit stockholder votes in favor of a Merger Agreement Proposal. The meeting is scheduled to reconvene on October 15, 2026.
Tarsus Pharmaceuticals M&A Deal with Alkeus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals filed an amendment to its previous 8-K to provide required historical and pro forma financial statements following its acquisition of Alkeus Pharmaceuticals. The acquisition was originally completed on September 4, 2026, pursuant to a merger agreement dated July 31, 2026.
Nephros, Inc. has scheduled its 2026 Annual Meeting of Stockholders for November 25, 2026, to be held virtually. Because the meeting date has shifted by more than 30 days from the anniversary of the previous year's meeting, the company has established new deadlines of October 23, 2026, for stockholder proposals and director nominations.
Credo Technology Group Holding CFO Daniel W. Fleming Sells $1.61M of Stock
Daniel W. Fleming, CFO, sold 7,580 shares of Credo Technology Group Holding Ltd at $211.28 to $215.08 a share (average $212.91) in 5 transactions, worth $1.61M in total on Oct 8, 2026. Shares held after the trade: 492,208 (-0.2%).
Escalon Medical Corp. reported a significant increase in net income to $4,012,626 for the fiscal year ended June 30, 2026, primarily driven by a $2,813,525 gain from the sale of AXIS software and a $1,139,449 income tax benefit. Total revenues grew slightly to $12.7 million, while the company strengthened its cash position to over $3 million by year-end.
Cytokinetics President & CEO Robert I. Blum Sells $472K of Stock
Robert I. Blum, President & CEO, sold 7,500 shares of Cytokinetics Inc at $62.88 a share, worth $472K in total on Oct 12, 2026. Shares held after the trade: 278,544 (-2.6%).
Niki BioSolutions, Inc. appointed Thomas Freeburg as Chief Financial Officer for a two-year term effective September 1, 2026. Mr. Freeburg's compensation package includes a base salary of $250,000 (increasing to $275,000 upon certain funding), an annual bonus of up to 50%, and 50,000 stock options at an exercise price of $8.83 per share.
Strategy Director Jarrod M. Patten Sells $422K of Stock
Jarrod M. Patten, Director, sold 2,750 shares of Strategy Inc at $150.54 to $158.00 a share (average $153.54) in 5 transactions, worth $422K in total between Oct 8, 2026 and Oct 9, 2026. Shares held after the trade: 28,406 (-1.6%).
Destra Multi-Alternative Fund Stock Buyback Update
Destra Multi-Alternative Fund authorized a new share repurchase program to support its market price when trading at a discount to NAV. The Fund also increased its monthly distribution to $0.1150 per share for the fourth quarter of 2026 and entered a measurement period regarding its potential term extension beyond March 2027.
Axia Energia Director de Lima Filho Pedro Batista Sells $1.21M of Stock
de Lima Filho Pedro Batista, Director, sold 105,100 shares of Axia Energia S.A. at $11.52 a share, worth $1.21M in total on Oct 9, 2026. Shares held after the trade: 4,847,931 (-0.2%).
Federal Home Loan Bank of Topeka $3.04B Debt Financing
Federal Home Loan Bank of Topeka issued a series of consolidated obligation bonds and notes totaling approximately $3.04 billion in par value. These debt securities are joint and several obligations of the eleven Federal Home Loan Banks and are used to fund the bank's operations in the capital markets.
Heico Co-COB and Co-CEO Victor H. Mendelson Buys $175K of Stock
Victor H. Mendelson, Co-COB and Co-CEO, bought 795 shares of Heico Corp at $220.30 a share, worth $175K in total on Oct 8, 2026. Shares held after the trade: 795.
Heico Insider Thomas M. Culligan Buys $175K of Stock
Thomas M. Culligan bought 795 shares of Heico Corp at $220.30 a share, worth $175K in total on Oct 8, 2026. Shares held after the trade: 11,825 (+7.2%).
Pimco California Municipal Income Fund Insider Bank of America Corp /De/ Buys $16.1K of Stock
Bank of America Corp /De/ bought 2,000 shares of Pimco California Municipal Income Fund at $8.04 a share, worth $16.1K in total on Oct 12, 2026. Shares held after the trade: 2,000.
Heico Insider Mark H. Hildebrandt Buys $175K of Stock
Mark H. Hildebrandt bought 795 shares of Heico Corp at $220.30 a share, worth $175K in total on Oct 8, 2026. Shares held after the trade: 50,218 (+1.6%).
Heico Insider Alan Schriesheim Buys $175K of Stock
Alan Schriesheim bought 795 shares of Heico Corp at $220.30 a share, worth $175K in total on Oct 8, 2026. Shares held after the trade: 1,202 (+195.3%).
Heico Insider Nandakumar Cheruvatath Buys $175K of Stock
Nandakumar Cheruvatath bought 795 shares of Heico Corp at $220.30 a share, worth $175K in total on Oct 8, 2026. Shares held after the trade: 4,877 (+19.5%).
AmBase $1.5M Debt Financing with Richard A. Bianco
AmBase Corporation entered into a letter agreement with its Chairman, President, and CEO, Richard A. Bianco, for an additional $1.5 million in litigation funding. This contribution is part of an existing Litigation Funding Agreement (LFA) to support working capital and ongoing legal expenses related to the 111 West 57th Property. The company continues to disclose a going concern qualification and is exploring further strategic alternatives to meet its capital needs.
BAB, Inc. reported a net income of $533,428 for the nine months ended August 31, 2026, an increase from $438,188 in the prior year period. Total revenues grew to $2.44 million, driven by higher royalty and marketing fund revenues, while the company maintained a strong cash position of $2.75 million.
Federal Home Loan Bank of Boston $710M Debt Financing
The Federal Home Loan Bank of Boston committed to issuing $710 million in consolidated obligation bonds across six tranches with maturities ranging from 2027 to 2031. These debt securities are the joint and several obligations of the 11 Federal Home Loan Banks and are used to fund the Bank's operations. The issuances include both non-callable variable rate floaters and fixed-rate bonds with optional redemption features.
5E Advanced Materials Director Hoff Graham vant Buys $215K of Stock
Hoff Graham vant, Director, bought 60,000 shares of 5E Advanced Materials, Inc. at $3.59 a share, worth $215K in total on Oct 8, 2026. Shares held after the trade: 102,997 (+139.5%).
MedWellAI, Inc. reported a net loss of $1,589,465 for the fiscal year ended June 30, 2026, an improvement from a $3,607,145 loss in 2025 as it transitioned from digital asset mining to the health and wellness industry. The company faces significant liquidity challenges with a stockholders' deficit of $7,979,411 and an accumulated deficit of over $90 million, leading to a substantial doubt about its ability to continue as a going concern.